NKTR-102: Clinical Trials

4 trials of NKTR-102, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed. 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 24Completed 4

Follow NKTR-102: new trials by email Literature Review of NKTR-102 trials Research Report on NKTR-102

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer
Pegylated Irinotecan - Stage IV Non-small Cell Lung Cancer (NSCLC), Recurrent Non-small Cell Lung Cancer (NSCLC)
Phase 2CompletedJoel Neal272015-08-012023-12-12
Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma
Etirinotecan pegol - Anaplastic Astrocytomas, Anaplastic Oligodendrogliomas
Phase 2CompletedLawrence Recht202012-07-012016-02-24
NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer
NKTR-102, irinotecan - Colorectal Cancer
Phase 2CompletedNektar Therapeutics832008-12-012021-07-12
Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Breast Cancer
NKTR-102 - Tumor, Breast Cancer
Phase 2CompletedNektar Therapeutics702008-10-012018-07-09

Conditions studied

Breast Neoplasms (2)  ·  Astrocytoma (1)  ·  Brain Neoplasms (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Colorectal Neoplasms (1)  ·  Glioblastoma (1)  ·  Neoplasms (1)  ·  Oligodendroglioma (1)  ·  Small Cell Lung Carcinoma (1)

Sponsors

Nektar Therapeutics (2)  ·  Joel Neal (1)  ·  Lawrence Recht (1)

Countries

United States (4)  ·  Belgium (2)  ·  United Kingdom (2)  ·  Germany (1)  ·  India (1)  ·  Spain (1)

Top investigators

Alison Hannah, MD (1)  ·  Joel Neal (1)  ·  Lawrence Recht, MD (1)

Results publications

PMID 24095299, PMID 40877204